Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 334 participants.
Also called NCT02177786
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 334 participants
- Sponsor
- Registry
-
NCT02177786
-
- Other papers using this trial's data
- Effects of Selonsertib in Patients with Diabetic Kidney Disease
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02177786. Randomized; double masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2016-07 (actual). Results posted on 2019-06-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- Selonsertib
- Intervention (Drug)
- Placebo to match selonsertib
- Lead sponsor
- Gilead Sciences
Record details
- Record id
cardio:ct-nct02177786- Content hash
622f887718ac08b54b12ad078e49efc72bef9209e3aaaddb548c1cd995378b87